The omega-3 index as biomarker

The omega-3 index is a blood test that measures how much EPA and DHA — the two key marine omega-3 fatty acids — are incorporated into red blood cell membranes, expressed as a percentage of all fatty acids present. Because RBC membranes turn over slowly, the result reflects weeks-to-months of dietary and supplemental omega-3 intake, making it a stable, long-term biomarker rather than a snapshot of yesterday's meal. The test was standardized by researcher William Harris and is now available through specialty labs at modest cost. Clinically, values above 8% are associated with lower cardiovascular and inflammatory disease risk, while most people in Western countries sit in the 3–5% range — well below that threshold. The index matters for resolution biology because EPA and DHA are the direct precursor substrates from which the body synthesizes specialized pro-resolving mediators (SPMs); a low index implies constrained SPM production capacity regardless of how well other aspects of health are managed. This makes it a practical stratification tool: clinicians can use it before and after an omega-3 intervention to confirm tissue-level uptake rather than relying on self-reported diet. Key open questions include whether the optimal threshold differs by condition, whether there is a ceiling beyond which more omega-3 adds no benefit, and whether DPA — an intermediate omega-3 with its own bioactivity — should be included in the calculation.

• An omega-3 index >8% is associated with cardioprotective status and generally lower chronic-inflammation markers; <4% is associated with high cardiovascular and inflammatory disease risk.
• Most Western populations cluster in the 3–5% range, while Japanese populations historically cluster at 9–11%; vegetarian/vegan populations without fish or algae supplementation frequently fall below 3%.
• The index serves as a proxy for SPM production capacity because EPA and DHA are the obligate precursor substrates for the major SPM families (resolvins, protectins, maresins), linking a simple blood test directly to resolution biology.

This is a mechanism review article, not a primary clinical trial; no original patient cohort or intervention arm is reported. The article synthesizes the standardized assay methodology — RBC phospholipid extraction, hydrolysis, and gas chromatography quantification of fatty acid composition — developed and validated by William Harris's reference laboratory. Interpretation thresholds are drawn from epidemiological and clinical data accumulated across multiple populations. As a review, no specific sample size, randomization, or follow-up period applies.

Because this is a mechanism review rather than a controlled trial, it cannot establish causal dose-response relationships between index values and clinical outcomes in specific disease states. The three-tier threshold system (>8%, 4–8%, <4%) is derived primarily from cardiovascular epidemiology and may not translate directly to inflammatory or resolution-specific endpoints. It remains unresolved whether optimal targets differ by condition (e.g., neurological vs. cardiometabolic), whether a meaningful ceiling effect exists, and whether DPA should be incorporated into the index. A next logical experiment would be a prospective trial co-measuring the omega-3 index alongside direct SPM plasma levels before and after supplementation to validate the index as a surrogate for resolution capacity.

This article extends [§19] by providing a practical clinical measurement layer on top of the conceptual framework that established resolution as an active, mediator-driven process — knowing that resolution is active demands a tool to assess substrate availability, which the omega-3 index supplies. It likewise extends [§20] by offering a standardized way to quantify the EPA and DHA precursor pools that directly determine biosynthetic capacity for the SPM families (resolvins, protectins, maresins) described there; low index values mechanistically predict constrained SPM output before a single mediator is assayed. The article parallels work on efferocytosis in atherosclerosis [§77] in that both converge on the same disease territory — chronic vascular inflammation — but approach it from different angles: [§77] examines the cellular clearance machinery downstream of resolution, while this article addresses the lipid substrate supply upstream of SPM synthesis.

• Resolution as an active process
  Establishes resolution as an active process requiring SPM production; reading alongside the omega-3 index review clarifies why measuring EPA+DHA substrate levels is mechanistically meaningful rather than merely correlational.
• Specialized pro-resolving mediators (SPMs)
  Describes the specific SPM families biosynthesized from EPA and DHA; directly complements the omega-3 index article by showing what the index is functionally predicting — the production capacity of resolvins, protectins, and maresins.
• Comprehensive analysis of efferocytosis-related genes in diagnosis and immune infiltration in atherosclerosis: based on bulk and single-cell RNA sequencing data
  Focuses on efferocytosis — the downstream cellular resolution mechanism in atherosclerosis — providing a disease-specific endpoint against which omega-3 index thresholds for cardiovascular risk could ultimately be validated.